Researchers identify DNA vulnerabilities that sensitize cancer cells to treatment
NYU Langone Health researchers have linked specific genomic sites to increased sensitivity to PARP inhibitor drugs in cancer cells.
Researchers at NYU Langone Health and the Perlmutter Cancer Center have identified specific DNA structures that dictate how cancer cells respond to medical intervention. The study reveals that a subset of vulnerable genomic sites, when damaged, renders cancer cells significantly more sensitive to PARP inhibitors—a class of drugs that prevents cancer cells from repairing their DNA.
The research utilized advanced imaging to track how cells react to damage in different regions of the genome. The findings suggest that the efficacy of PARP inhibitors is not uniform across all cancer cells but is instead dependent on the specific location of the genomic instability. This provides a clearer picture of the biological mechanisms behind treatment resistance and success.
This study offers potential for refining patient care by identifying those most likely to benefit from targeted therapy. Future efforts will focus on translating these genomic insights into clinical biomarkers to improve patient outcomes.